Physician profile
Brian Douglas Dewitt
NPI 1841627049
$2,824.79
in general payments reported to CMS, 2019-2025
19 companies · $929 in 2025
The $929 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $26.52 · 2021: $170 · 2022: $556 · 2023: $494 · 2024: $506 · 2025: $929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,930.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,929.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $1,072.17 | 2022-2025 | Azstarys |
| Glaxosmithkline, LLC. | $302.88 | 2019-2025 | Bexsero, Pediarix |
| Pfizer INC. | $281.89 | 2019-2025 | |
| Cranial Technologies, INC | $247.84 | 2019-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $241.88 | 2021-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Sanofi Pasteur INC. | $148.94 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $135.03 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $81.30 | 2019-2024 | |
| Sobi, INC | $44.81 | 2019-2022 | |
| Lnhc, INC | $42.79 | 2025 | Zelsuvmi |
| Phadia US INC. | $42.16 | 2024 | Immunocap |
| Seqirus USA INC | $41.99 | 2023-2025 | Flucelvax Quadrivalent, Flucelvax |
| Vertical Pharmaceuticals, LLC | $23.29 | 2025 | Relexxii |
| Biomarin Pharmaceutical INC. | $23.28 | 2021 | |
| Abbott Laboratories | $23.10 | 2025 | Id Now Instrument |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $21.30 | 2024 | Qelbree |
| Photonicare INC | $18.85 | 2025 | Otosight Middle Ear Scope |
| Glenmark Therapeutics INC. | $16.00 | 2019 | |
| Noven Therapeutics, LLC | $15.29 | 2025 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Dewitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.